您的位置:澳门金莎娱乐网址 > 生命科学 > 设计蛋白为癌症疗法研究开启了新的思路

设计蛋白为癌症疗法研究开启了新的思路

发布时间:2019-08-22 03:48编辑:生命科学浏览(59)

    核心提示:胶质母瘤细胞通路示意图 美国研究人员在靶向攻击和破坏致死型脑部肿瘤—&图片 1

    "

    "目录号: HY-14407A

    "目录号: HY-13757

    H. Pandya, D. M. Gibo, W. Debinski. Molecular Targeting of Intracellular Compartments Specifically in Cancer Cells. Genes & Cancer, 2010; DOI: 10.1177/1947601910375274

    GPCR/G ProteinNeuronal Signaling-

    GPCR/G ProteinNeuronal Signaling-

    OthersAutophagy-

    关键词:设计蛋白 癌症治疗

    Fosaprepitant(L-758298)???????????????-1?????????????????????????????????????????????????????????????????????

    Fosaprepitant dimeglumine(MK-0517)是神经激肽-1受体拮抗剂,可作用于化疗引起的恶心呕吐。

    Tamoxifen Citrate 是一种抗雌激素,抑制雌激素结合到雌激素受体 (estrogen receptors)。

    Neurokinin Receptor

    Neurokinin Receptor

    Estrogen Receptor/ERRAutophagy

    相关产品

    相关产品

    相关产品

    Aprepitant-Maropitant-Fosaprepitant dimeglumine-Netupitant-Talnetant-NKP608-SB-222200-Rolapitant-Substance P-Befetupitant-Fezolinetant-Hemokinin 1 mouse-Kassinin-MEN11467-Neurokinin A-

    Aprepitant-Maropitant-Netupitant-Talnetant-NKP608-SB-222200-Rolapitant-Substance P-Befetupitant-Fosaprepitant-Fezolinetant-Hemokinin 1 mouse-Kassinin-MEN11467-Neurokinin A-

    Cycloheximide-TAK-242-LY294002-3-Methyladenine-( )-JQ-1-SB 203580-SP600125-U0126-Enzalutamide-Actinomycin D-Olaparib-Doxorubicin hydrochloride-Dorsomorphin dihydrochloride-Mitomycin C-Bortezomib-

    生物活性

    生物活性

    生物活性

    Description

    Description

    Description

    Fosaprepitant (L-758298) is a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.IC50 Value:Target: NK1 receptorin vitro: Fosaprepitant (also known as MK-0517 and L-758,298) is a water-soluble phosphoryl prodrug for aprepitant, which, when administered intravenously, is converted to aprepitant within 30 min of intravenous administration via the action of ubiquitous phosphatases. Owing to the rapid conversion offosaprepitant to the active form (aprepitant), fosaprepitant 115 mg provided the same aprepitant exposure in terms of AUC as aprepitant 12 mg orally, and fosaprepitant is expected to provide a correspondingly similar antiemetic effect as aprepitant [1]. in vivo: Fosaprepitant is well tolerated with mild to moderate venous irritation being the only additional toxicity to those seen with oral aprepitant, and that is a function of dose, concentration, and infusion rate [2]. Patients receiving cisplatin ??? 70 mg/m(2) for the first time received ondansetron and dexamethasone with a standard aprepitant regimen (125 mg on day 1, 80 mg on day 2, 80 mg on day 3) or a single-dose fosaprepitant regimen (150 mg on day 1) [3]. Single-dose fosaprepitant used in combination with granisetron and dexamethasone was well-tolerated and effective in preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic cancer chemotherapy, including high-dose cisplatin [4].

    Fosaprepitant dimeglumine(MK-0517) is a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.IC50 Value:Target: NK1 receptorin vitro: Fosaprepitant (also known as MK-0517 and L-758,298) is a water-soluble phosphoryl prodrug for aprepitant, which, when administered intravenously, is converted to aprepitant within 30 min of intravenous administration via the action of ubiquitous phosphatases. Owing to the rapid conversion offosaprepitant to the active form (aprepitant), fosaprepitant 115 mg provided the same aprepitant exposure in terms of AUC as aprepitant 12 mg orally, and fosaprepitant is expected to provide a correspondingly similar antiemetic effect as aprepitant [1]. in vivo: Fosaprepitant is well tolerated with mild to moderate venous irritation being the only additional toxicity to those seen with oral aprepitant, and that is a function of dose, concentration, and infusion rate [2]. Patients receiving cisplatin ≥ 70 mg/m(2) for the first time received ondansetron and dexamethasone with a standard aprepitant regimen (125 mg on day 1, 80 mg on day 2, 80 mg on day 3) or a single-dose fosaprepitant regimen (150 mg on day 1) [3]. Single-dose fosaprepitant used in combination with granisetron and dexamethasone was well-tolerated and effective in preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic cancer chemotherapy, including high-dose cisplatin [4].

    Tamoxifen Citrate is an antiestrogen by inhibiting the binding of estrogen toestrogen receptors.

    Clinical Trial

    Clinical Trial

    IC50& Target

    NCT01874119

    NCT01874119

    Estrogen receptor[1];)

    St. Louis University-Merck Sharp & Dohme Corp.

    St. Louis University-Merck Sharp & Dohme Corp.

    In Vitro

    Chemotherapy-induced Nausea and Vomiting

    Chemotherapy-induced Nausea and Vomiting

    Tamoxifen shows strong inhibition of MCF-7 cells (EC50=1.41 μM) and to a lesser extent the T47D cells (EC50=2.5 μM) but does not affect the MDA-MB-231 cells[2];).

    September 2013

    September 2013

    In Vivo

    Phase 2

    Phase 2

    The Tamoxifen-inducible gene knockout strategy has clear advantages in that expression of a gene can be ablated in adult mice at will in a tissue specific manner. To study the role of Med1 in adult heart, 7-week old TmcsMed1-/-mice are given a daily Iintraperitoneal injection of Tamoxifen at a dose of 65 mg/kg for 5 days and killed at selected intervals thereafter. qPCR analysis of RNA shows that the Med1 expression begin to decrease after 3 days of Tamoxifen injection (about 70% decrease), and by 5 days of injection, Med1 expression is almost non-detectable in the heart. Tamoxifen-inducible cardiac-specific disruption of Med1 (TmcsMed1-/-) in adult mice causes dilated cardiomyopathy[3];).

    NCT02407600

    NCT02407600

    Clinical Trial

    Ajeet Gajra-Merck Sharp & Dohme Corp.-State University of New York - Upstate Medical University

    Ajeet Gajra-Merck Sharp & Dohme Corp.-State University of New York - Upstate Medical University

    NCT02513849

    Non-small Cell Lung Cancer-Vomiting-Nausea-Emesis

    Non-small Cell Lung Cancer-Vomiting-Nausea-Emesis

    University of Nottingham

    April 2015

    April 2015

    Cancer-Gastrointestinal Neoplasms

    Phase 2

    Phase 2

    December 2015

    NCT03197064

    NCT03197064

    Phase 1

    Stanford University

    Stanford University

    NCT01027416

    Postoperative Nausea

    Postoperative Nausea

    Roswell Park Cancer Institute-National Institutes of Health (NIH)-National Cancer Institute (NCI)

    August 1, 2017

    August 1, 2017

    Breast Cancer

    Phase 4

    Phase 4

    December 14, 2009

    NCT01736917

    NCT01736917

    NCT00749138

    Lawrence Einhorn-Hoosier Cancer Research Network-Merck Sharp & Dohme Corp.

    Lawrence Einhorn-Hoosier Cancer Research Network-Merck Sharp & Dohme Corp.

    Bader, Ted, M.D.

    Chemotherapy-Induced Nausea and Vomiting

    Chemotherapy-Induced Nausea and Vomiting

    Chronic Hepatitis C

    January 2013

    January 2013

    November 2008

    Phase 2

    Phase 2

    Phase 1

    NCT01405924

    NCT01405924

    NCT00532454

    Merck Sharp & Dohme Corp.

    Merck Sharp & Dohme Corp.

    National Cancer Center, Korea

    Nausea-Vomiting

    Nausea-Vomiting

    Breast Cancer-Metastatic Disease

    October 2011

    October 2011

    June 2006

    Phase 2

    Phase 2

    Phase 2

    NCT02519842

    NCT02519842

    NCT00165308

    Merck Sharp & Dohme Corp.

    Merck Sharp & Dohme Corp.

    Dana-Farber Cancer Institute-Brigham and Women's Hospital-Massachusetts General Hospital-AstraZeneca

    Chemotherapy-induced Nausea and Vomiting

    Chemotherapy-induced Nausea and Vomiting

    Hodgkin's Disease-Breast Cancer

    September 2015

    September 2015

    April 2001

    Phase 3

    Phase 3

    NCT02197897

    NCT01432015

    NCT01432015

    Baylor College of Medicine-National Cancer Institute (NCI)

    Gynecologic Oncology Associates-Merck Sharp & Dohme Corp.

    Gynecologic Oncology Associates-Merck Sharp & Dohme Corp.

    Bladder Cancer

    Ovarian Cancer-Uterine Cancer

    Ovarian Cancer-Uterine Cancer

    June 2015

    September 2011

    September 2011

    Phase 2

    Phase 4

    Phase 4

    NCT02089386

    NCT00945321

    NCT00945321

    Washington University School of Medicine

    Merck Sharp & Dohme Corp.

    Merck Sharp & Dohme Corp.

    Barrett Metaplasia

    Chemotherapy-Induced Nausea and Vomiting

    Chemotherapy-Induced Nausea and Vomiting

    July 9, 2014

    February 2009

    February 2009

    Early Phase 1

    Phase 1

    Phase 1

    NCT01192308

    NCT01344304

    NCT01344304

    Radboud University

    Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group

    Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group

    Breast Cancer

    Colorectal Cancer

    Colorectal Cancer

    July 2010

    April 2011

    April 2011

    Phase 1

    NCT01504711

    NCT01504711

    NCT02668666

    Philip Philip-National Cancer Institute (NCI)-Barbara Ann Karmanos Cancer Institute

    Philip Philip-National Cancer Institute (NCI)-Barbara Ann Karmanos Cancer Institute

    Oana Danciu, MD-Pfizer-Big Ten Cancer Research Consortium

    Gastrointestinal Cancer-Nausea Post Chemotherapy

    Gastrointestinal Cancer-Nausea Post Chemotherapy

    Hormone Receptor Positive Malignant Neoplasm of Breast-Human Epidermal Growth Factor 2 Negative Carcinoma of Breast-Estrogen Receptor Positive Breast Cancer-Progesterone Receptor Positive Tumor-Metastatic Breast Cancer

    June 2012

    June 2012

    June 2016

    NCT01031953

    NCT01031953

    Phase 2

    OHSU Knight Cancer Institute-National Cancer Institute (NCI)

    OHSU Knight Cancer Institute-National Cancer Institute (NCI)

    NCT00710970

    Breakthrough Nausea and Vomiting-Unspecified Adult Solid Tumor, Protocol Specific

    Breakthrough Nausea and Vomiting-Unspecified Adult Solid Tumor, Protocol Specific

    Seth Lerner-AstraZeneca-Cytogen Corporation-Baylor College of Medicine

    August 2008

    August 2008

    Urinary Bladder Neoplasms

    Phase 1-Phase 2

    Phase 1-Phase 2

    January 2007

    NCT01594749

    NCT01594749

    Phase 2

    Merck Sharp & Dohme Corp.

    Merck Sharp & Dohme Corp.

    NCT02166944

    Chemotherapy-Induced Nausea and Vomiting (CINV)

    Chemotherapy-Induced Nausea and Vomiting (CINV)

    Taipei Medical University Shuang Ho Hospital

    September 2012

    September 2012

    Amyotrophic Lateral Sclerosis-ALS Functional Ration Scale-TAR-DNA-binding Protein-43-Tamoxifen-mTOR

    Phase 3

    Phase 3

    April 2014

    NCT00818259

    NCT00818259

    Phase 1-Phase 2

    Merck Sharp & Dohme Corp.

    Merck Sharp & Dohme Corp.

    NCT01075802

    Chemotherapy-Induced Nausea and Vomiting

    Chemotherapy-Induced Nausea and Vomiting

    Western Sydney Local Health District-St George Hospital, Australia

    February 5, 2009

    February 5, 2009

    Breast Cancer-CYP2D6 Polymorphism

    Phase 1

    Phase 1

    March 2010

    NCT01074697

    NCT01074697

    NCT02824224

    Odense University Hospital-Helsinn Healthcare SA

    Odense University Hospital-Helsinn Healthcare SA

    Oregon Health and Science University

    Nausea-Vomiting-Genital Neoplasms, Female

    Nausea-Vomiting-Genital Neoplasms, Female

    Menorrhagia-Metrorrhagia-Medicated Intrauterine Devices

    April 2010

    April 2010

    September 2016

    Phase 3

    Phase 3

    Phase 4

    NCT01490060

    NCT01490060

    NCT00309491

    M.D. Anderson Cancer Center-Merck Sharp & Dohme Corp.

    M.D. Anderson Cancer Center-Merck Sharp & Dohme Corp.

    Austrian Breast & Colorectal Cancer Study Group

    Sarcoma-Chemotherapy-induced Nausea and Vomiting-Effects of Chemotherapy-Adverse Effects of Medical Drugs

    Sarcoma-Chemotherapy-induced Nausea and Vomiting-Effects of Chemotherapy-Adverse Effects of Medical Drugs

    Early-stage Breast Cancer

    May 2012

    May 2012

    December 1990

    NCT01697579

    NCT01697579

    Phase 3

    Merck Sharp & Dohme Corp.

    Merck Sharp & Dohme Corp.

    NCT00764322

    Chemotherapy-induced Nausea and Vomiting

    Chemotherapy-induced Nausea and Vomiting

    UNC Lineberger Comprehensive Cancer Center-National Cancer Institute (NCI)

    December 13, 2012

    December 13, 2012

    Breast Cancer-Menopausal Symptoms

    Phase 2

    Phase 2

    June 2008

    NCT01649258

    NCT01649258

    Phase 2

    University of Southern California-National Cancer Institute (NCI)

    University of Southern California-National Cancer Institute (NCI)

    NCT00206492

    Breast Cancer-Nausea-Vomiting

    Breast Cancer-Nausea-Vomiting

    Baylor Breast Care Center-AstraZeneca

    September 4, 2012

    September 4, 2012

    Breast Cancer

    NCT01111851

    NCT01111851

    July 2003

    Merck Sharp & Dohme Corp.

    Merck Sharp & Dohme Corp.

    Phase 2

    Chemotherapy-Induced Nausea and Vomiting (CINV)

    Chemotherapy-Induced Nausea and Vomiting (CINV)

    NCT02322853

    April 2010

    April 2010

    Centre Francois Baclesse-National Cancer Institute, France-ARC Foundation for Cancer Research

    Phase 1

    Phase 1

    Postmenopausal-Metastatic Breast Cancer

    NCT00895245

    NCT00895245

    January 2015

    University of Washington-National Cancer Institute (NCI)

    University of Washington-National Cancer Institute (NCI)

    Phase 2

    Nausea and Vomiting-Stage III Squamous Cell Carcinoma of the Hypopharynx-Stage III Squamous Cell Carcinoma of the Larynx-Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity-Stage III Squamous Cell Carcinoma of the Nasopharynx-Stage III Squamous Cell Carcinoma of the Oropharynx-Stage IV Squamous Cell Carcinoma of the Hypopharynx-Stage IV Squamous Cell Carcinoma of the Larynx-Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity-Stage IV Squamous Cell Carcinoma of the Nasopharynx-St

    Nausea and Vomiting-Stage III Squamous Cell Carcinoma of the Hypopharynx-Stage III Squamous Cell Carcinoma of the Larynx-Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity-Stage III Squamous Cell Carcinoma of the Nasopharynx-Stage III Squamous Cell Carcinoma of the Oropharynx-Stage IV Squamous Cell Carcinoma of the Hypopharynx-Stage IV Squamous Cell Carcinoma of the Larynx-Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity-Stage IV Squamous Cell Carcinoma of the Nasopharynx-St

    NCT02988986

    February 2009

    February 2009

    Jenny C. Chang, MD-Millennium Pharmaceuticals, Inc.-The Methodist Hospital System

    Phase 2

    Phase 2

    Estrogen Receptor Positive Breast Cancer

    NCT00619359

    NCT00619359

    April 24, 2017

    Merck Sharp & Dohme Corp.

    Merck Sharp & Dohme Corp.

    Phase 2

    Chemotherapy-Induced Nausea and Vomiting (CINV)

    Chemotherapy-Induced Nausea and Vomiting (CINV)

    NCT01257581

    February 2008

    February 2008

    Nazem Atassi-ALS Therapy Alliance-State University of New York - Upstate Medical University-Massachusetts General Hospital

    Phase 3

    Phase 3

    Amyotrophic Lateral Sclerosis

    NCT03035838

    NCT03035838

    March 2011

    Arun Gupta-Cambridge University Hospitals NHS Foundation Trust-University of Cambridge

    Arun Gupta-Cambridge University Hospitals NHS Foundation Trust-University of Cambridge

    Phase 2

    Traumatic Brain Injury

    Traumatic Brain Injury

    NCT02488603

    September 2017

    September 2017

    National Cancer Center, Korea

    Early Phase 1

    Early Phase 1

    Breast Cancer

    NCT02106494

    NCT02106494

    August 2015

    Heron Therapeutics

    Heron Therapeutics

    NCT02070692

    Chemotherapy-induced Nausea and Vomiting

    Chemotherapy-induced Nausea and Vomiting

    Oregon Health and Science University-Society of Family Planning

    March 2014

    March 2014

    Menstruation Disturbances

    Phase 3

    Phase 3

    February 2014

    NCT02732015

    NCT02732015

    Phase 4

    M.D. Anderson Cancer Center-Tesaro, Inc.

    M.D. Anderson Cancer Center-Tesaro, Inc.

    NCT01189500

    Sarcoma

    Sarcoma

    Pfizer

    October 2016

    October 2016

    Pharmacokinetics

    Phase 2

    Phase 2

    August 2010

    NCT00337727

    NCT00337727

    Phase 4

    Merck Sharp & Dohme Corp.

    Merck Sharp & Dohme Corp.

    NCT00896155

    Chemotherapy-Induced Nausea and Vomiting

    Chemotherapy-Induced Nausea and Vomiting

    Tata Memorial Hospital-Indian Council of Medical Research

    January 1, 2007

    January 1, 2007

    Pulmonary Fibrosis-Breast Cancer

    Phase 3

    Phase 3

    December 2008

    NCT01857232

    NCT01857232

    Phase 3

    Acacia Pharma Ltd

    Acacia Pharma Ltd

    NCT00900744

    CINV

    CINV

    Icahn School of Medicine at Mount Sinai

    October 2013

    October 2013

    Breast Cancer

    Phase 2

    Phase 2

    January 2009

    NCT02116530

    NCT02116530

    Phase 4

    Alliance for Clinical Trials in Oncology-National Cancer Institute (NCI)

    Alliance for Clinical Trials in Oncology-National Cancer Institute (NCI)

    NCT01194427

    Hematopoietic/Lymphoid Cancer-Nausea and Vomiting-Unspecified Adult Solid Tumor, Protocol Specific

    Hematopoietic/Lymphoid Cancer-Nausea and Vomiting-Unspecified Adult Solid Tumor, Protocol Specific

    Sidney Kimmel Comprehensive Cancer Center-Merck Sharp & Dohme Corp.

    August 2014

    August 2014

    Stage I Breast Cancer-Stage II Breast Cancer-Stage III Breast Cancer-Invasive Breast Cancer

    Phase 3

    Phase 3

    March 2011

    NCT00990821

    NCT00990821

    Phase 2

    Merck Sharp & Dohme Corp.

    Merck Sharp & Dohme Corp.

    NCT00973037

    Chemotherapy-Induced Nausea and Vomiting-Postoperative Nausea and Vomiting

    Chemotherapy-Induced Nausea and Vomiting-Postoperative Nausea and Vomiting

    Korea University Anam Hospital-National Cancer Center, Korea-Korean Breast Cancer Study Group

    January 2005

    January 2005

    Breast Neoplasms-Tamoxifen-Genotype-CYP2D6

    Phase 1

    Phase 1

    March 2009

    NCT00231777

    NCT00231777

    NCT00295646

    Merck Sharp & Dohme Corp.

    Merck Sharp & Dohme Corp.

    Austrian Breast & Colorectal Cancer Study Group-AstraZeneca-Novartis Pharmaceuticals

    Post-Operative Nausea and Vomiting

    Post-Operative Nausea and Vomiting

    Breast Cancer

    July 2005

    July 2005

    June 1999

    Phase 3

    Phase 3

    Phase 3

    View MoreCollapse

    View MoreCollapse

    NCT02482740

    References

    References

    Buddhist Tzu Chi General Hospital-Chang Gung Memorial Hospital-Chung Shan Medical University-China Medical University Hospital-National Cheng-Kung University Hospital-Kaohsiung Medical University Chung-Ho Memorial Hospital-Kaohsiung Veterans General Hospital.-Taiwan Ministry of Science and Technology

    [1].Navari RM. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2008 Nov;8(11):1733-42.

    [1].Navari RM. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2008 Nov;8(11):1733-42.

    Uterine Cervical Neoplasms

    [2].Olver IN. Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant. Ther Clin Risk Manag. 2008 Apr;4(2):501-6.

    [2].Olver IN. Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant. Ther Clin Risk Manag. 2008 Apr;4(2):501-6.

    May 2015

    [3].Grunberg S, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol. 2011 Apr 10;29(11):1495-501.

    [3].Grunberg S, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol. 2011 Apr 10;29(11):1495-501.

    Phase 2

    [4].Saito H, et al. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol.

    [4].Saito H, et al. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol.

    NCT02936206

    Icahn School of Medicine at Mount Sinai-AstraZeneca

    Breast Cancer

    October 2016

    Phase 1

    NCT01579734

    European Institute of Oncology

    Breast Cancer

    March 2002

    Phase 3

    NCT01196936

    University of Alabama at Birmingham-National Cancer Institute (NCI)-St. Jude Children's Research Hospital-University Health Network, Toronto-University of Michigan-Dana-Farber Cancer Institute-Mayo Clinic-University of Washington-City of Hope National Medical Center-M.D. Anderson Cancer Center-University of Chicago-University of Minnesota - Clinical and Translational Science Institute-University of Colorado, Denver-Wake Forest University

    Breast Cancer

    September 2010

    Phase 2

    NCT00687102

    Wake Forest University-National Institute on Aging (NIA)-Wake Forest University Health Sciences

    Cognition-Aging

    October 2001

    Phase 3

    NCT03112031

    Oxford University Clinical Research Unit, Vietnam-Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam-Cho Ray Hospital, Ho Chi Minh City, Vietnam-University of Liverpool-University of Rochester-Liverpool School of Tropical Medicine

    Meningitis Streptococcal-Hiv-Meningitis-Meningoencephalitis

    August 1, 2017

    Phase 2

    NCT00424164

    European Organisation for Research and Treatment of Cancer - EORTC

    Breast Cancer

    November 2006

    Phase 1

    NCT02285179

    The Netherlands Cancer Institute-Genentech, Inc.-EurocanPlatform-Rather

    Breast Cancer-Ovarian Cancer-Cancer of the Uterus

    November 2014

    Phase 1

    NCT02806544

    Vanderbilt University-Washington University School of Medicine-Instituto National de Cancerologia, Guatemala

    Breast Cancer-Breast Neoplasms

    January 2013

    Phase 2

    NCT00365599

    H. Lee Moffitt Cancer Center and Research Institute-Merck Sharp & Dohme Corp.

    Breast Cancer

    February 2006

    Phase 2

    NCT03045653

    Sun Yat-sen University

    Breast Cancer Metastatic

    February 1, 2017

    Phase 2

    NCT00286117

    AstraZeneca-Institute of Cancer Research, United Kingdom

    Breast Cancer

    March 1998

    Phase 3

    NCT00912548

    Korean Breast Cancer Study Group

    Breast Cancer

    May 2009

    Phase 3

    NCT02344940

    Shanghai Jiao Tong University School of Medicine

    Breast Cancer

    December 2014

    Phase 4

    NCT02690870

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University-Sun Yat-sen University

    Infertility

    January 2017

    Phase 4

    NCT02801786

    Universidade Federal de Goias

    Pain-Discomfort

    July 2016

    Phase 2-Phase 3

    NCT00963209

    Centre Hospitalier Universitaire Vaudois

    Breast Cancer

    June 2009

    Phase 3

    NCT00919399

    Institut

    本文由澳门金莎娱乐网址发布于生命科学,转载请注明出处:设计蛋白为癌症疗法研究开启了新的思路

    关键词: